OLHHA
OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD).
For research use only. We do not sell to patients.
- CAS No.: 1258011-97-0
- Formula: C27H45NO3
- Molecular Weight:431.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10863
Anandamide
-
HY-110016
Docosatetraenylethanolamide
-
HY-110004
ACEA
-
HY-113421
Linoleoyl ethanolamide
-
HY-139394
Arachidonoyl-1-thio-glycerol
-
HY-121517
URB754
-
HY-130567
1-Monoarachidin
-
HY-110003
Arachidonylcyclopropylamide
-
HY-112528
Glycerophospho-N-palmitoyl ethanolamine
-
HY-113070
Dihomo-γ-Linolenoyl Ethanolamide
-
HY-121476
Arachidonoyl Serinol
-
HY-124089S
Eicosapentaenoyl ethanolamide-d4
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8- to 9-week-old male Zucker rats (genetic obesity)[2]
-
Dosage:5 mg/kg
-
Administration:I.p.; daily for 15 days
-
Result:Reduced the liver fat content and plasma triglyceride levels, and this was accompanied by a general improvement in the profile of plasma parameters related to liver damage in the obese rats, significantly reduced the body weight gain and decreased in the relative expression of CB1 in lean rats.
Chemical Information
-
CAS No. 1258011-97-0
-
Molecular Weight 431.65
-
Formula C27H45NO3
-
SMILES
CCCCCCCC/C=C\CCCCCCCC(NC(C)CC1=CC=C(O)C(O)=C1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Alen F, et al. PPARα/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. Biochem Pharmacol. 2018 Nov;157:235-243. [Content Brief]
[2]. Decara JM, et al. Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats. Dis Model Mech. 2015 Oct 1;8(10):1213-25. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
OLHHA Related Classifications
HY-139230 Related Classifications
Powered by Bioz